Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 9/20 | 0.53 |
| ▸ | PPARG | P37231 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935652 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2PPARAPPARGLMNANPSR1 | |
| SCHEMBL7255301 | 0.87 | PPARG (0.64) | SMN1; SMN2PPARAPPARGLMNAHTT | |
| SCHEMBL28049294 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARAPPARGNPSR1 | |
| SCHEMBL2280554 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARAPPARGNPSR1HTT | |
| SCHEMBL4651839 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL295888 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL14122548 | 0.84 | LMNA (0.47) | SMN1; SMN2PPARAPPARGLMNANPSR1 | |
| SCHEMBL14121890 | 0.84 | LMNA (0.47) | SMN1; SMN2PPARAPPARGLMNANPSR1 | |
| SCHEMBL14121887 | 0.84 | LMNA (0.47) | SMN1; SMN2PPARAPPARGLMNANPSR1 | |
| SCHEMBL30475592 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARAPPARGLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579868-B1 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECH INC (US) | 2018-03-07 | — | — | EP | claimed |
| US-9402864-B2 | Oral iron deficiency therapy | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-08-02 | — | — | US | claimed |
| US-20130230604-A1 | ORAL IRON DEFICIENCY THERAPY | Emispere Technologies, Inc. (US) | 2013-09-05 | — | — | US | claimed |
| EP-2579868-A2 | ORAL IRON DEFICIENCY THERAPY | Emisphere Technologies, Inc. (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2011156563-A2 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-12-15 | — | — | WO | claimed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2579868-B1 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECH INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011156563-A2 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-1070487-C | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2001-09-05 | — | — | CN | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| CN-1098099-A | The hexahydro naphthalene ester derivative, their preparation and their treatment are used | SANKYO CO (JP) | 1995-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | SMN1; SMN2 4185/4885PPARA 2/4885PPARG 1/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | SMN1; SMN2 2595/4885PPARA 868/4885PPARG 504/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | SMN1; SMN2 4185/4885PPARA 2/4885PPARG 1/4885 |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | PPARG, CDK5R1, CDK5 | SMN1; SMN2 3918/4885PPARA 5/4885PPARG 1/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SMN1; SMN2 3872/4885PPARA 2/4885PPARG 1/4885 |
| US-20130230604-A1 | ORAL IRON DEFICIENCY THERAPY | SLC40A1, FECH, HAMP | SMN1; SMN2 2766/4885PPARA 1689/4885PPARG 1534/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SMN1; SMN2 3872/4885PPARA 2/4885PPARG 1/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | SMN1; SMN2 3872/4885PPARA 2/4885PPARG 1/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SMN1; SMN2 3872/4885PPARA 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.